That the sell side is high and .002 is looming. With reports stating that an update is upon us, the sell side suggests things arn't all that rosey.Lets hope I'm wrong....
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%